Tsutomu Murakami

Tsutomu Murakami


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2022 in Biology
Verified
Journal Article
Open access
PDF file
TMTsutomu Murakami
Tsutomu Murakami
Tomoyoshi KomiyamaTomoyoshi Komiyama
Tomoyoshi Komiyama
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
YIYuji Ikari
Yuji Ikari
Most patients with Takotsubo Syndrome (TTS) are postmenopausal females. TTS in males is rare and gender differences have not been sufficiently investigated. Therefore, we investigated gender differences in TTS. TTS in males and females is often triggered by physical and emotional stress, respectively. Heart failure, a severe in-hospital complication, requires greater mechanical respiratory support in males. Fatal arrhythmias such as ventricular tachycardia and ventricular fibrillation and in-hospital mortality rates are higher in males. The white blood cell (WBC) count has been shown to be higher in males than in females with cardiovascular death compared with non-cardiovascular death. Therefore, the WBC count, a simple marker, may reflect severe TTS. Decreased estrogen levels, common in postmenopausal females, are a pathogenic mechanism of TTS. Females have a more significant increase in the extracellular matrix-receptor interaction than males. Moreover, the pathological findings after hematoxylin–eosin staining were different in males and females. Males had more severe complications than females in the acute phase of TTS; thus, more careful observations and interventions are likely required. From these results, it can be considered that the mechanism of the onset of TTS may be different between males and females. Therefore, it is necessary to fully understand the gender differences in order to more effectively manage TTS.

1 September 1997 in Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
NTNanako Takeda‐Hirokawa
Nanako Takeda‐Hirokawa
LNLian‐Pin Neoh
Lian‐Pin Neoh
HAHiroaki Akimoto
Hiroaki Akimoto
HKHiroshi Kaneko
Hiroshi Kaneko
THTakashi Hishikawa
Takashi Hishikawa
YKYutaro Kaneko
Yutaro Kaneko
To clarify the mechanism by which curdlan sulfate (CRDS) inhibits human immunodeficiency virus (HIV)‐1 infection, we examined its influence on the binding of gp120 to CD4 molecules on T cells and macrophages, as well as on the production of TNF‐α by gp120‐stimulated macrophages (which promotes HIV‐1 replication). CRDS treatment of cells not only inhibited the binding of HIV‐1 gp120 to CD4+ cells, but also inhibited TNF‐α production induced by gp120. Inhibition of HIV‐1 infection by CRDS may be related to these two actions.

28 January 2025 in European Heart Journal
Verified
Journal Article
Open access
SMShingo Matsumoto
Shingo Matsumoto
YOYohei Ohno
Yohei Ohno
SNSatoshi Noda
Satoshi Noda
JMJunichi Miyamoto
Junichi Miyamoto
NKNorihiko Kamioka
Norihiko Kamioka
KHKentaro Hayashida
Kentaro Hayashida
Background and Aims: The association between periprocedural change in tricuspid regurgitation (TR) and outcomes in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER) is unclear. This study aimed to examine the prognostic value of TR before and after M-TEER. Methods: Patients in the OCEAN-Mitral registry were divided into four groups according to baseline and post-procedure echocardiographic assessments: no TR/no TR (no TR), no TR/significant TR (new-onset TR), significant TR/no TR (normalized TR), and significant TR/significant TR (residual TR) (all represents before/after M-TEER). Tricuspid regurgitation ≥ moderate was defined as significant. The primary outcome was cardiovascular death or heart failure hospitalization. Tricuspid regurgitation pressure gradient was also evaluated. Results: The numbers of patients in each group were 2103 (no TR), 201 (new-onset TR), 504 (normalized TR), and 858 (residual TR). Baseline assessment for TR and TR pressure gradient was not associated with outcomes after M-TEER. In contrast, patients with new-onset TR had the highest adjusted risk for the primary outcome, followed by those with residual TR [compared with no TR as a reference, hazard ratio 1.83 (95% confidence interval: 1.39–2.40) for new-onset TR, 1.45 (1.23–1.72) for residual TR, and 0.82 (0.65–1.04) for normalized TR]. Similarly, from baseline to post-procedure, TR pressure gradient changes were associated with subsequent outcomes after M-TEER. New-onset and residual TR incidence was commonly associated with dilated tricuspid annulus diameter and atrial fibrillation. Conclusions: Post-procedural TR, but not baseline TR, was associated with outcomes after M-TEER. Careful TR assessment after the procedure would provide an optimal management for concomitant significant TR in patients undergoing M-TEER.

21 May 2021 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
TMTsutomu Murakami
Tsutomu Murakami
Tomoyoshi KomiyamaTomoyoshi Komiyama
Tomoyoshi Komiyama
SMShingo Matsumoto
Shingo Matsumoto
HKHiroshi Kajiwara
Hiroshi Kajiwara
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
YIYuji Ikari
Yuji Ikari
Background: Takotsubo syndrome is a stress-induced disease that makes up 2–3% of acute coronary syndrome cases. However, its onset mechanism remains unclear. Although females are overwhelmingly affected, males end up having more cardiac complications.Case presentation: We examined the differences in stress responses in the myocardium between sexes in patients with takotsubo syndrome. We biopsied samples from an over 70-year-old Japanese male and an over 80-year-old Japanese female. Tissues from the left ventricle apex in the acute phase and the apical ballooning-type were examined using histopathology and deoxyribonucleic acid (DNA) microarray analysis. Our data showed that left ventricular ejection fractions were 38% and 56%, and peak creatinine kinase concentrations during hospitalization were 629 U/L and 361 U/L, for the male and female patient, respectively. The pulmonary capillary wedge pressure was 26 mmHg and 11 mmHg for the male and female patient, respectively. Negative T did not return to normal in the male subject after 6 months. Histopathology results indicated that contraction band necrosis and lymphocyte infiltration were more common in the male subject.Conclusions: We noticed that possible differences may exist between male and female patients using pathological examination and some DNA analyses. In particular, it may help treat acute severity in males. We will elucidate the mechanism of takotsubo syndrome development by increasing the number of samples to support the reliability of the data in the future.

1 August 2023 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
TSTakafumi Saito
Takafumi Saito
MNMakoto Natsumeda
Makoto Natsumeda
TSTakato Sakagami
Takato Sakagami
TMTsutomu Murakami
Tsutomu Murakami
STShunsuke Takagi
Shunsuke Takagi
YIYuji Ikari
Yuji Ikari
Background: Takotsubo syndrome (TTS) is an acute and usually reversible heart failure syndrome characterized as an uncommon left ventricular (LV) cardiomyopathy. Recurrence of TTS is rare, estimated to be 1–6%. We report a rare case of TTS that occurred three times in 2 months but manifested various phenotypes. Case summary: A 68-year-old woman was admitted to our hospital with acute-onset chest pain and hypertension. The coronary angiography findings were normal, although left ventriculography revealed inferior wall hypokinesis, leading to a mid-ventricular TTS diagnosis. She was discharged on Day 3 after her symptoms improved and vitals stabilized. The patient’s condition remained uneventful until 2-week post-discharge, when acute chest pain and hypertension recurred. She was admitted again with the same diagnosis. However, LV morphology revealed an apical ballooning pattern, with inferior LV wall hypokinesis. She was discharged on Day 7 after her symptoms and electrocardiography findings improved but was readmitted again 2 weeks later after acute chest pain and hypertension recurred. Left ventriculography performed a third time demonstrated mid-ventricular TTS. The patient was prescribed additional medications and discharged on Day 12. Her electrocardiography findings normalized, and the patient remained asymptomatic without recurrence 4 months after the initial presentation. Discussion: Recurrence and phenotypic change of TTS are rare. Some cases have been reported but occurring months to years after initial diagnosis. Combined treatment with β-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists may be more effective to prevent the recurrence than monotherapies.

26 November 2025 in JACC: Asia
Verified
Journal Article
Open access
TNTenjin Nishikura
Tenjin Nishikura
KYKo Yamamoto
Ko Yamamoto
KWKohei Wakabayashi
Kohei Wakabayashi
MNMasahiro Natsuaki
Masahiro Natsuaki
HWHirotoshi Watanabe
Hirotoshi Watanabe
TKTakeshi Kimura
Takeshi Kimura
Safety of proton pump inhibitors (PPIs) in patients undergoing percutaneous coronary intervention (PCI) with aspirin-free P2Y12 inhibitor monotherapy was unknown. The authors aimed to evaluate effects of PPIs in patients undergoing PCI with P2Y12 inhibitor monotherapy. We compared outcomes between patients with and without PPI prescription in the STOPDAPT-3 trial enrolling patients undergoing PCI stratified by the no-aspirin (1-month prasugrel monotherapy followed by clopidogrel monotherapy: n = 2,909 [acute coronary syndrome: n = 2,170, high bleeding risk: n = 1,580]) and the aspirin (1-month dual antiplatelet therapy followed by aspirin monotherapy: n = 2,914 [acute coronary syndrome: n = 2,171, high bleeding risk: n = 1,566]) strategies at 1 year. PPIs were prescribed in 2,418 patients (83.1%) with the no-aspirin strategy, and in 2,695 patients (92.5%) with the aspirin strategy. In the propensity score matched cohort (no-aspirin strategy: n = 902 and aspirin strategy: n = 376), a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke more often occurred in the PPI group than in the no-PPI group with the no-aspirin strategy (7.1% vs 2.4%, P = 0.002), but not with the aspirin strategy (6.9% vs 7.4%, P = 0.817). Death also more often occurred in the PPI group than in the no-PPI group with the no-aspirin strategy, but not with the aspirin strategy. Incidence of major bleeding was not different between the groups regardless of the no-aspirin and aspirin strategies (5.5% vs 3.3%, P = 0.150, and 6.9% vs 4.3%, P = 0.278) CONCLUSIONS: PPI use was associated with higher risks of cardiovascular events and mortality without decreasing major bleeding in patients undergoing PCI with aspirin-free P2Y12 inhibitor monotherapy. (ShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-3 [STOPDAPT-3]; NCT04609111).